The BCL-2 inhibitor Venetoclax augments immune effector function mediated by Fas lognad TRAIL, and Perforin/Granzyme B, resulating in reduced plasma viremia and decreased HIV reservoir size during acute HIV infection in a humanized mouse model

HIV-1 Vpu restricts Fc-mediated effector functions in vivo

No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long- term ART

Limited impact of fingolimod treatment during the initial weeks of ART in SIV-infected rhesus macaques

Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound

An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection

Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses

The role of Cd101-expressing CD4 T cells in HIV/SIV pathogenesis and persistence

Temsavir treatment of HIV-1-infected cells decreases envelope glycoprotein recognition by broadly neutralizing antibodies

Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control

Novel role of UHRF1 in the epigenetic repression of the latent HIV-1

Novel Compound Inhibitors of HIV-1 NL4-3 Vpu